Cited by 29Thyroid Disorders and TreatmentsGenomics and Rare DiseasesImmunodeficiency and Autoimmune Disorders

A novel IGSF 1 mutation in a large Irish kindred highlights the need for familial screening in the IGSF 1 deficiency syndrome

Open access
Roche, Edna F., McGowan, Anne, Koulouri, Olympia, Turgeon, Marc‐Olivier, Nicholas, Adeline K., Heffernan, Emmeline, El‐Khairi, Ranna, Abid, Noina +8 more·2018·Clinical Endocrinology

Abstract

Summary: Objective: Loss‐of‐function mutations in IGSF 1 result in X‐linked central congenital hypothyroidism (Ce CH), occurring in isolation or associated with additional pituitary hormone deficits. Intrafamilial penetrance is highly variable and a minority of heterozygous females are also affected. We identified and characterized a novel IGSF 1 mutation and investigated its associated phenotypes in a large Irish kindred. Design, Patients and Measurements: A novel hemizygous IGSF 1 mutation was identified by direct sequencing in two brothers with Ce CH, and its functional consequences were characterized in vitro. Genotype‐phenotype correlations were investigated in the wider kindred. Results: The mutant IGSF 1 protein (c.2318T > C, p.L773P) exhibited decreased plasma membrane expression in vitro due to impaired trafficking from the endoplasmic reticulum. Ten hemizygous males and 11 heterozygous females exhibited characteristic endocrine deficits. Ireland operates a TSH‐based CH screening programme, which does not detect Ce CH; therefore, genetic ascertainment preceded biochemical diagnosis of moderate CH in five of seven boys as well as their 75‐year‐old grandfather. Clinical features potentially attributable to hypothyroidism were variable; normal free T3 (FT 3) and low/low normal reverse T3 (rT 3) concentrations suggested that preferential deiodination of FT 4 to FT 3 may help maintain tissue euthyroidism in some individuals. However, neonatal jaundice, delayed speech or growth, and obesity were observed in seven subjects in whom diagnosis was delayed. Conclusions: As observed with other IGSF 1 mutations, p.L773P results in variably penetrant IGSF 1 deficiency syndrome. Our observations emphasize the need for multi‐generation genetic ascertainment in affected families, especially where TSH‐based CH screening programmes may fail to detect Ce CH at birth.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.13827

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Serum rT3 typically rises as T3 falls during nonthyroidal illness; consequently, measurement of rT3 adds little to this diagnosis unless nonthyroidal illness is confounding the diagnosis of central hypothyroidism.

    “Serum rT3 typically rises as T3 falls during nonthyroidal illness; consequently, measurement of rT3 adds little to this diagnosis unless nonthyroidal illness is confounding the diagnosis of central hypothyroidism.”

    From Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status (2023) · cites this paper as [89]

    The Results (Thyroid function) and Discussion report normal FT3 with low or low-normal rT3 in people with IGSF1-related central hypothyroidism. Searches for nonthyroidal illness and the diagnostic value of rT3 found no passage addressing the claimed pattern during nonthyroidal illness or the proposed exception for diagnosing central hypothyroidism. The reported IGSF1 findings concern a different condition and do not establish or contradict the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Impaired bioactivity of circulating TSH has been prevalently demonstrated by in vitro bioassays, but can also be supported in vivo by impaired increment of free T4 and/or T3 following TSH response upon TRH stimulation test.

    “The impaired bioactivity of circulating TSH has been prevalently demonstrated by in vitro bioassays (15), but this phenomenon can also be supported in vivo by the impaired increment of circulating free T4 and/or T3 following the TSH response upon TRH stimulation test (18, 19).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Roche, E. F., McGowan, A., Koulouri, O., Turgeon, M., Nicholas, A. K., Heffernan, E., El‐Khairi, R., Abid, N., Lyons, G., Halsall, D., Bonomi, M., Persani, L., Dattani, M. T., Gurnell, M., Bernard, D. J., & Schoenmakers, N.
Affiliations
  • Trinity College Dublin (IE)
  • University of Cambridge (GB)
  • McGill University (CA)
  • Royal Belfast Hospital for Sick Children (GB)
  • Wellcome/MRC Cambridge Stem Cell Institute (GB)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • University of Milan (IT)
  • University College London (GB)
Corresponding author
Schoenmakers, Nadia
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2018-10
Volume
89
Issue
6
Pages
813-823
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2885272002
Cited by
29
References
36
Citations by year
2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 11 · 2019: 4
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Clinical Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, cc-by)
Funders
  • Wellcome Trust (100574/Z/12/Z, 100585/Z/12/Z)
  • National Institute for Health Research
  • Canadian Institutes of Health Research (MOP‐133557)
  • Natural Sciences and Engineering Research Council of Canada (2015‐05178)
  • Ministero della Salute (RF‐2010‐2309484)
  • Medical Research Council (MRC_MC_UU_12012/5)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
IGSF1, novel mutations, hemizygous mutation, family screening, genotype-phenotype correlation, penetrance, reverse T3, delayed diagnosis
MeSH terms
Adolescent, Adult, Aged, Child, Child, Preschool, Congenital Hypothyroidism, Female, Humans, Immunoglobulins, Infant, Ireland, Male, Membrane Proteins, Middle Aged, Mutation, Thyroxine, Triiodothyronine, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review